- Home
- FMFC vs ACHV Comparison
FMFC vs ACHV Comparison
Compare FMFC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMFC
- ACHV
- Stock Information
- Founded
- FMFC 2016
- ACHV N/A
- Country
- FMFC Cambodia
- ACHV United States
- Employees
- FMFC N/A
- ACHV N/A
- Industry
- FMFC
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- FMFC
- ACHV Health Care
- Exchange
- FMFC NYSE
- ACHV Nasdaq
- Market Cap
- FMFC 84.4M
- ACHV 72.5M
- IPO Year
- FMFC 2025
- ACHV N/A
- Fundamental
- Price
- FMFC $6.27
- ACHV $2.31
- Analyst Decision
- FMFC
- ACHV Strong Buy
- Analyst Count
- FMFC 0
- ACHV 3
- Target Price
- FMFC N/A
- ACHV $14.33
- AVG Volume (30 Days)
- FMFC 1.2M
- ACHV 1.3M
- Earning Date
- FMFC 01-01-0001
- ACHV 08-12-2025
- Dividend Yield
- FMFC N/A
- ACHV N/A
- EPS Growth
- FMFC N/A
- ACHV N/A
- EPS
- FMFC 0.06
- ACHV N/A
- Revenue
- FMFC $15,486,220.00
- ACHV N/A
- Revenue This Year
- FMFC N/A
- ACHV N/A
- Revenue Next Year
- FMFC N/A
- ACHV N/A
- P/E Ratio
- FMFC $101.00
- ACHV N/A
- Revenue Growth
- FMFC 3.71
- ACHV N/A
- 52 Week Low
- FMFC $4.20
- ACHV $1.84
- 52 Week High
- FMFC $6.50
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- FMFC N/A
- ACHV 39.39
- Support Level
- FMFC N/A
- ACHV $2.02
- Resistance Level
- FMFC N/A
- ACHV $3.90
- Average True Range (ATR)
- FMFC 0.00
- ACHV 0.26
- MACD
- FMFC 0.00
- ACHV -0.10
- Stochastic Oscillator
- FMFC 0.00
- ACHV 17.37
About FMFC KANDAL M VENTURE LIMITED
Kandal M Venture Ltd is engaged in manufacturing affordable luxury leather goods. The company manufactures handbags, such as shoulder bags, crossbody bags, tote bags, backpacks, top-handle handbags, satchels, and other smaller leather goods, such as wallets. Geographically, the company derives maximum revenue from the United States.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.